AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer
May 5-8, 2022
Westin Copley Place
Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, California
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, New York
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France
Liver cancer is a major health problem, the 4th leading cause of cancer-related deaths globally. By 2025 the incidence of liver cancer is estimated to reach 1 million individuals. There have been major advances in the understanding of the pathogenesis and treatment of the two main types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Still, most patients do not present at a curative stage and outcomes are often less than optimal in at-risk populations.
This inaugural program will feature international leaders in the field who will review the role of the tumor microenvironment, immune involvement, and the microbiome in the pathogenesis of liver cancer. Understanding the mechanism of action of current treatments, biomarkers predicting response, trial design, liquid biopsy and rationale for future combinations will also be explored.
Please join in the conversation, with basic scientists, physician-scientists, and industry professionals all united towards the common goal of improving research and management of this aggressive disease.